Coherus Oncology: Setting Up For Important Readouts In Mid-2026

Coherus Oncology (CHRS) remains a Buy as I maintain optimism around its advancing immunotherapy pipeline despite recent market negativity. Key catalysts include mid-2026 data readouts for casdozokitug in HCC and ongoing pivotal JUPITER-02 trial for toripalimab in nasopharyngeal carcinoma. CHRS's liquidity covers 2–3 quarters at current cash burn; further financing may be needed before pivotal clinical milestones.

Seeking Alpha • 12 hours ago

Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript

Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 12, 2026

Coherus Oncology Q1 Earnings Call Highlights

Coherus Oncology NASDAQ: CHRS said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts across its oncology pipeline later this year.

MarketBeat • May 11, 2026

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug, CCR8 Treg depleter development expands with pharmacological and clinical program differentiation, including dose-responsive immune effects, no off-target binding, acceptable safety – – $167.0 million in quarter-end cash, cash equivalents and marketable securities – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif.

GlobeNewsWire • May 11, 2026

Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates

Coherus Oncology (CHRS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.35 per share a year ago.

Zacks Investment Research • May 11, 2026

Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026. Starting at 5:00 p.m. Eastern Time on May 11, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

GlobeNewsWire • May 4, 2026

Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know

Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Mar 25, 2026

Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript

Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 10, 2026

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year ending cash, cash equivalents and marketable securities – – Conference call today at 4:30 p.m. Eastern Standard Time – REDWOOD CITY, Calif.

GlobeNewsWire • Mar 9, 2026

Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates

Coherus Oncology (CHRS) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.28 per share a year ago.

Zacks Investment Research • Mar 9, 2026